AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

GLP-1 receptor agonists (GLP-1RAs) were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management ...

The global market for acute migraine treatment is on a steady growth trajectory, with sales expected to rise from USD 2,700.7 million in 2024 to USD 4,194.1 million by 2034, reflecting a CAGR of 4.5% ...

Senators ask if contracts between drugmakers and telehealth companies violate the federal anti-kickback statute.

The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As ...

U.S. drugmakers Johnson & Johnson and Eli Lilly increased spending on security for their top executives in 2024, citing ...

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The latest research report published by Vantage Market Research, titled "An Increase in Demand and Opportunities for the ...

New York, New York-- (Newsfile Corp. - March 9, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. (NASDAQ: BIOA) and ...